Oncotarget is ranked first among Oncology journals for the total number of documents published. The mission of the publication is to share scientific results as widely and as rapidly as possible to facilitate insightful review and maximize the impact of the research. Oncotarget works to ensure exceptional discoveries are quickly shared and borders between specialties are eliminated. They hope to link all fields of biomedical science so basic and clinical science applications will be used to fight disease. Upon special demand, each paper or issue can be printed.
Oncotarget is an open access medical journal founded in 2010. Peer-reviewed and published weekly by Impact Journals, Oncotarget offers coverage on research dealing with all aspects of oncology. Roswell Park Cancer Institute researchers Andrei Gudkov and Mikhail Blagosklonny, the publication’s editors-in-chief. The multidisciplinary journal is published online and offers free access. Abstracted and indexed in the Science Citation Index Expanded, BIOSIS Previews, Index Medicus/MEDLINE/PubMed and Scopus, Oncotarget has an Impact Factor of 5.415.
Articles may be reprinted, downloaded and distributed but the original source and authors must be cited.
Oncotarget aims to maximizing the impact of research being done to fight disease.
Led by some of oncology’s most prominent scientists, Oncotarget gives researchers an outlet which enables them to contribute to scientific progress. Authors whose work has been published in Oncotarget include Nobel Prize winner Andrew Schally and Breakthrough Prize winners Stephen J. Elledge, Michael Hall, Alexander Varshavsky and Bert Vogelstein. The publication’s multiple constructive, insightful, timely peer-reviews and interviews with outstanding authors and researchers has led to its rising popularity.
The term “oncotarget” covers all the molecules, cellular functions and pathways that are common when dealing with cancer and aging, cancer cells and microbes, lymphocytes and neurons as well as neurodegeneration and atherosclerosis. Oncotarget’s success has lead the publisher to add sections that go beyond oncology. They now accept papers on topisc like Cardiology, Cell Biology, Endocrinology, Metabolism, Neuroscience, Pharmacology and more. Oncotarget also sponsors the Gordon Research Conference. The ultimate goal of the publication is enable all scientist, researchers and clinicians to contribute to life without disease. Read more about Mikhail at LinkedIn.com